Podcast appearances and mentions of Jerry Lee

Send us a textShow: I Almost Got Away With ItEpisode: Season 1 Episode 3Jerry Lee Bowen tells his own story of how he lived life as a fugitive. being on the run from justice isn't as sexy as Harrison Ford makes it out to be. Jerry Lee isn't sexy is also a problem. When his ex-wife disappears, everyone immediately thinks Jerry Lee did it. Well, he did. Support the showCheck out our website: https://www.buzzsprout.com/837988 Linktree: https://linktr.ee/itsalwaysthehusbandpodcast Like our Facebook page and join our group!! Instagram: @itsalwaysthehusbandpodcast Twitter: @alwaysthehubs Etsy Shop: https://www.etsy.com/shop/ItsAlwaysTheHusband?ref=simple-shop-header-name&listing_id=776055218 Theme song by Jamie "I'm Gonna Kill You, Bitch" Nelson

Episode 185: Jerry Lee W/E Street Band, Leeds Music, Blue Jays, Fogelberg March 31, 2025 Going back to the first airing of episode 30 on RadioFreeNashville.org and November 2022, we'll play Jerry Lee Lewis and Springsteen's Band at the opening of the Rock n Roll Hall of Fame, which, looking at recent inductees, should be remarqueed Hall of Music (Pop). Live at Leeds was regarded by some as one of the, if not THE best recorded live albums, along with The Allmans at Fillmore East. There's some shakin' going on there too. The entire hour is filled with a lot of the great LP cuts that made the 60s & 70s music so important. I want to say thank you to all the financial supporters of Tales Vinyl Tells. Whether a small amount monthly or a very generous donation, each of you listeners are very appreciated and if you can and do give monthly, my deepest gratitude goes to you. If you're not a patron yet and want to know more about becoming a patron of this music program you can go Patron.podbean.com/talesvinyltellssupport. Thank you and rock on! And thanks for listening today.  My email is talesvinyltells@gmail.com.  If you want to hear a Tales Vinyl Tells when it streams live on RadioFreeNashville.org, we do that at 5 PM central time Wednesdays. The program can also be played and downloaded anytime at podbean.com, Apple podcasts, iHeart podcasts, Player FM podcasts and many other podcast places. And of course you can count on hearing the Tales on studiomillswellness.com/tales-vinyl-tells anytime.

Author Jeff Apter joins us again to discuss his excellent new book, Carl Perkins: The King of Rockabilly. In the annals of rock history, Carl often gets overlooked as colleagues like Elvis, Jerry Lee, and Johnny take center stage. He'd probably be fine with that. But his story is fascinating. Writing "Blue Suede Shoes" and being a key influence on the Beatles kept him viable his entire life. Jeff tells a beautiful story of a wonderful man with a fascinating history that many of us may not know that much about. Enjoy! www.jeffapter.com.au  

durée : 00:05:33 - Jouez au piano dans une gare, filmez-vous et participer au concours "A vous de jouer" à Brest - Une âme de Mozart ou de Jerry Lee lewis ? Amateur ou professionnel, enfant ou adulte, à vous de jouer sur l'un des 70 pianos en accès libre en France, donc deux en Bretagne à Rennes et Brest

Mattson, Alec and JJ delve into the cinematic showdown between the canine-centric films "K9" and "Turner and Hooch," both released in 1989. The primary focus of our discussion revolves around the nuanced performances of the titular dogs and the emotional resonance inherent in their respective narratives. We explore the overtly comical antics of Jerry Lee in "K9," contrasted with the heartfelt journey of Turner and Hooch as they navigate the complexities of human-animal relationships. Our dialogue is enriched by personal anecdotes and a critical examination of comedic elements, leading us to assess the films' merits and shortcomings in terms of humor, action, and emotional depth. Ultimately, we arrive at a consensus on the enduring appeal of these films, each contributing uniquely to the landscape of canine cinema.Support us:https://www.patreon.com/whatsourverdictEmail us: hosts@whatsourverdict.comFollow us:Facebook: https://www.facebook.com/whatsourverdictTwitter: @whatsourverdictInstagram: @whatsourverdictYouTube: https://youtube.com/channel/UC-K_E-ofs3b85BnoU4R6liAVisit us:www.whatsourverdict.com

The night before Jerry Lee Lewis' fifth wife died, she made a phone call to her mother. She told her that she was thinking of leaving the rock ‘n' roll pioneer, but that he wouldn't let her. She also made a second call—this one to the sister of her high school sweetheart, making plans for the sister to come take her away from Jerry Lee later that month. Then … in mid-sentence the phone went dead. The next day, Mrs. Jerry Lee Lewis was found dead. Placed nearly on top of a perfectly made bed in the newlywed couple's guest room. Despite the bruises on her body, the blood under her fingernails, the scratches on her husband's hands, and the mountain of other physical and anecdotal evidence, the death was ruled an accident. Did Jerry Lee Lewis kill his wife and get away with murder? To see the full list of contributors, see the show notes at www.disgracelandpod.com. This episode was originally published on February 13, 2018. To listen to Disgraceland ad free and get access to a monthly exclusive episode, weekly bonus content and more, become a Disgraceland All Access member at disgracelandpod.com/membership. Sign up for our newsletter and get the inside dirt on events, merch and other awesomeness - GET THE NEWSLETTER Follow Jake and DISGRACELAND: Instagram YouTube X (formerly Twitter)  Facebook Fan Group TikTok To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Mészáros Tamás a Magyarock Dalszínház színésze és énekese több mint egy évtizede kelti életre Jerry Lee Lewist a Made In Hungária színpadán. Az ikonikus színdarab felújított változatának premierje már dübörög vételkörzet-szerte. Az interjúból kiderül, hogyan talált rá Tamásra ez a szerep, és milyen kihívásokkal néz szembe, amikor színpadra lép?A Sláger FM-en minden este 22.10-kor a kultúráé a főszerep S. Miller András az egyik oldalon, a másikon pedig a térség kiemelkedő színházi kulturális, zenei szcena résztvevői.Inspiráló beszélgetések, valódi értékek, Budapest és Pest megye pezsgő kulturális életének legjava, aktuális történetekkel. Sláger KULT – A természetes emberi hangok műsora#slagerkult #smillerandras

CURRENT (ADVENT) SERMON SERIES: Waiting Room [ December 1 – December 22 ] Waiting. Waiting for the phone to ring. Waiting for the test results. Waiting for the traffic to clear. Waiting for the storm to pass. Waiting for the light to change. Waiting for your ship to come in. Waiting for the other shoe to drop. Waiting for the show to start. Waiting for the sun to rise. Waiting for a girl like you. Waiting on the world to change. We spend so much of our lives waiting for whatever it is we fear we do not have and believe we cannot live without—and we know all too well that, as Tom Petty famously crooned, the waiting is the hardest part. But what are we really waiting for? What are you waiting for? Maybe, in the end, what we're all really waiting for is for our waiting to finally be over—to be delivered from the chronic sense of lack and the expectancy of what might be, and to finally be at peace with what is, with who we are, with what we have, right here, right now. Advent is a time to acknowledge our lack and to wait patiently for that day when our waiting will finally be over and the peace we all long for finally won. In the coming of Emmanuel, God-with-Us, our waiting is at last fulfilled, and we have all we need to be who we are and to live as we are meant to live, right here, right now.

Take the younger brother of a famous comedian trying to make his own name and a police dog that doesn't play by the rules, and you get K-9, the 1989 film starring James Belushi and Rando the German Shepherd as Jerry Lee. It's a mystery that James Belushi needs to solve, and only Jerry Lee can help. --- Support this podcast: https://podcasters.spotify.com/pod/show/thegenxfiles/support

This week, Jason is joined by job market expert and COO of Wonsulting, Jerry Lee! Jerry shares his career history including his time at Google and working his way up, impact of having a mentor, how he overcame doubts, his best advice to getting your foot in the door, LinkedIn hacks, the power in consistency, how he utilizes monetization on LinkedIn, what Wonsulting does, resources you should know about, debunking certain career advice, and so much more! It's an episode you can't afford to miss!  Host: Jason Tartick Co-Host: David Arduin Audio: John Gurney Guest: Jerry Lee Stay connected with the Trading Secrets Podcast!  Instagram: @tradingsecretspodcast  Youtube: Trading Secrets Facebook: Join the Group All Access: Free 30-Day Trial 

CURRENT SERMON SERIES: "I AM" Who is Jesus? Some call him a teacher. Some a prophet, a rabbi, a radical, a political revolutionary. Those who believe in him often call him Lord, Savior, Son of God, forgiver of sins, friend to the lost. But what did Jesus call himself? In this sermon series, we'll look at the “I AM” sayings of Jesus from the Gospel of John and come to know him not by all the names Christians have given him over the centuries, but by the names he gave himself, and by the ordinary ways he desired to be known. We'll finish the series with a “bonus track” by Yahweh, who reminds us that “I Am,” in the end, just is.

Jim Loftus is now seven months into his role as CEO of Times-Shamrock Communications.Before joining the company, where he spent nine years as Chief Operations Officer earlier in his career, Loftus served as the Chief Operations Officer of 7 Mountains Media. Before that, he served as President/CEO of WBEB-FM in Philadelphia under the ownership of Jerry Lee.How are things going for this owner of radio stations, out-of-home and digital media in Northeast Pennsylvania, as well as radio stations in Milwaukee and a stand-alone operation in Baltimore?Loftus shares all in this InFOCUS Podcast, presented by dot.FM.

CURRENT SERMON SERIES: "Out of the Question" Some teachers answer questions. Others question the answers. But for Jesus, the answers to some of our biggest problems often came out of the questions he asked us. While Jesus is generally thought of as giving a lot of answers, he was actually full of really important questions. According to the Gospels, Jesus asked 307 questions. In contrast, he directly answered only three of the 183 questions he was ever asked. Jesus asked questions that could be easily answered and questions with no obvious answer. Most often, he answered the questions of others with questions of his own. In this series, we'll explore some of the most challenging questions Jesus ever asked—and, along the way, discover that the answers we search for are often revealed in the very questions themselves.

CURRENT SERMON SERIES: "Out of the Question" Some teachers answer questions. Others question the answers. But for Jesus, the answers to some of our biggest problems often came out of the questions he asked us. While Jesus is generally thought of as giving a lot of answers, he was actually full of really important questions. According to the Gospels, Jesus asked 307 questions. In contrast, he directly answered only three of the 183 questions he was ever asked. Jesus asked questions that could be easily answered and questions with no obvious answer. Most often, he answered the questions of others with questions of his own. In this series, we'll explore some of the most challenging questions Jesus ever asked—and, along the way, discover that the answers we search for are often revealed in the very questions themselves.

A few years ago I had the opportunity to see the great Jerry Lee Lewis in concert.  As fun as it was, he was pretty old...he could barely make it on stage, let alone jump on the bench while playing the piano As fate would have it, however my wife and I had season tickets to the Utah Symphony where today's guest was performing a "Jerry Lee Lewis" type tribute Dave Bennett's show was the exact opposite of Jerry Lee's show Dave jumped on the bench while pounding on the piano The energy was infectious! And, through a photo we posted on social media of Dave doing his thing we got connected Dave and I found we had a mutual love for jazz, rock and roll and classic bodybuilding Join me for an engaging conversation with this dynamic performer about his life, his career and how taking control of his health has helped him perform and have more energy at his 40th birthday than ever before!

This week's show, after a 1995 GBV gutting: brand new Decemberists, Jesus & Mary Chain, Finnogun's Wake, Lemon Twigs, Blushing, Nick Kizirnis, and Otherworldly Things, plus B.B. King, Tomorrow, Max Romeo, Junior Wells, Gerry & the Pacemakers, Jerry Lee...

Join correspondent Tom Wilmer in Tuolumne County, California for a visit with Sierra Repertory Theatre's executive Director, Scott Viets and artistic director Jerry Lee.

JCO PO authors Lauren C. Leiman and Dr. Emma Alme share insights into their JCO PO article, “Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care”. Host Dr. Rafeh Naqash and guests discusses increasing access to liquid biopsy for cancer, reviewing the barriers and examining the proposed solutions. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor of Medicine at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Lauren Leiman, Executive Director of BloodPAC, and Dr. Emma Alme, Public Policy Director at Guardant Health. They are both authors of the JCO Precision Oncology article titled "Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care."  Our guest disclosures will be linked in the transcript.  For the sake of this conversation, we will refer to each other using our first names. So, Lauren and Emma, welcome to the podcast and thank you for joining us today. Lauren Leiman: Thank you for having us. Dr. Emma Alme: Thank you so much.  Dr. Rafeh Naqash: So, this article is an opinion piece that addresses something that is emerging and current and tries to connect it to something that is futuristic also and hopefully, will address a lot of different needs relevant to patients with cancer. For starters, since our audience is pretty diverse, could you tell us what the BloodPAC is? Since the article is somewhat a combined piece from different stakeholders, could you explain what this BloodPAC Consortium is as an entity and what is its role for this BloodPAC? Lauren Leiman: Sure, this is Lauren Leiman. The BloodPAC was formed almost seven years ago as an initial commitment to the White House Cancer Moonshot back in 2016. I was the head of external partnerships and had this idea with a colleague of mine, Dr. Jerry Lee: Could you accelerate the development and approval of liquid biopsy assays for cancer patient benefit if you were able to create some standards and frameworks for the field broadly, and also if you could aggregate data to support those standards and frameworks? So, we brought together about 20 different organizations across pharmaceutical companies, diagnostic partners, foundations funding in the space, government agencies, all to think through can we create these frameworks, are we willing to submit data. We were extremely successful in that first round, and by the end of 2016, we were able to have our first data deposit into- we built a BloodPAC Data Commons, which is housed in Chicago and was created by Dr. Bob Grossman up there. In 2017, when it became clear that the last administration was not going to continue the White House Cancer Moonshot, we became an independent non-profit 501(c)(3). And we have grown substantially since that time from those original 20 different organizations to about 66 different organizations today, across all those areas again, including today, payers, which is very exciting. And we have added on to our mission statement one word that we will discuss today, which is very exciting, which is “accessibility”. After our five-year anniversary and even slightly before then, we decided that we really feel that we have been able to contribute, as a community, to accelerating the development and approval of these tests. But, in actuality if we don't get them into patients' hands, what is the point of all of our hard work? So, we added the word "accessibility." Today, we have these 66 different organizations that collaborate, essentially, to compete. They're pulling together projects and deliverables in about ten different working group areas to contribute products to the liquid biopsy community to help accelerate those three things. Dr. Rafeh Naqash: Thank you for explaining that. That seems like a very important initiative.  Now, when you say that you're contributing data, does it mean that different companies and entities are contributing patient-level data so that you can pool that and assess what is the utilization, what is the utility, what is the payer-related aspects, coverage aspects. Is that all part of the initiative?  Lauren Leiman: It is. We started with the idea, which is kind of scary, I think, for a lot of different companies: Are you willing to submit your protocols essentially, pre-analytical data? I think, much to the FDA's surprise, I was kind of, “Of course, everyone should be willing to do this, they should absolutely do this, it'll be really exciting. Why wouldn't they?” And I think others were a little skeptical that these companies who are highly competitive including Emma's company, Guardant, would be willing to contribute data. And in fact, Guardant is probably one of the first ones, first two at the table to actually submit their data which was just extremely exciting. And the data was around mostly protocols and pre-analytical variables, what tube types are you using? As we moved on, our pharmaceutical partners did submit full clinical trials with deidentified patient data, which was extremely exciting.   Today, our Data Commons sits in two different areas or visibilities for our members. One is membership-only data that only our members can see, so have been been contributed by them potentially sometimes for certain projects we're working on. And then we also have an open segment of our Data Commons that's open to the public, that includes published data and studies that anyone can take a look at and see. Our goal is to continue to open up all of our data over time, so that anyone can take a look at it. We are, I think, the leading liquid biopsy repository.  As we move into the future though, I think because we are mostly an organization that has pharmaceutical companies and diagnostic partners, we are company driven, aggregating large sums of research data is not necessarily their goal. And so to try to identify an area of mutually beneficial interests for everyone, I do think that over the next year or two, you'll see a potential shift or pivot in the use of Data Commons to where the industry is today which is probably, hopefully a little bit more coverage focused. How do we pivot from being a source of aggregated research to a source of identifying and approving the value of liquid biopsy to the full community? And again, that's for the full spectrum all the way through payers and the coverage of these tests, which I do think would add a tremendous amount of value to everyone on the life cycle of this industry but would also add a tremendous amount of value for access in getting these tests into patients' hands.  Dr. Rafeh Naqash: Of course, you importantly covered a bunch of different concepts. One is data democratization, which is extremely important in the current day and age for different people in the public domain if they have access to data, they can do a lot of interesting and important things and add to the overall understanding of what we know or don't know in this space of liquid biopsy utilization. And then, of course, the aspect of disparities and coverage assessments.  Now, going to Emma, for the sake of our listeners, some of them are trainees, and many of them are oncologists, perhaps many are patients. What is the current landscape for liquid biopsies? Where do we use them, and what are the general approaches and principles of where things stand?  Dr. Emma Alme: That's a great question, and it really spans the cancer care continuum. And I think the space where it's most established is in the advanced cancer stage for therapy selection. So that's where we actually have some even FDA approved assays for liquid biopsy, with Guardant 360 test being one of them. It's comprehensive genomic profiling to identify actionable biomarkers to get patients on targeted therapy. So that's where it's really been integral to precision medicine. And we're seeing an increase in utilization of liquid biopsy as the technology becomes more established. It's not just in cases where tissue is insufficient now. Most recently, we've seen NCCN guidelines and non-small cell lung cancer change for concurrent testing for liquid biopsies. So that's been an exciting trend in adoption.   And then as you move across the cancer care continuum, there's residual disease monitoring and response, where we can actually use ctDNA to look at a patient's response to therapy, even after surgery - is there still ctDNA there? Instead of just having imaging as an option, we can actually look sooner to see how the patient is responding and if there is still cancer present. So that's a really exciting place where we're seeing growth in liquid biopsy. And then moving even earlier, before a patient even has cancer, there's a tremendous opportunity for liquid biopsy in early cancer detection. I think that's something that has been previously discussed on this podcast and we see it a lot in popular media. But it's not just for multi-cancer, we have the opportunity for single cancer as well liquid biopsy tests in cancer screening.  That's a really exciting space, really thinking about the accessibility of these tests. Because a lot of cancer screening modalities today are hard for a lot of patients to access. And it requires going to a medical facility. So if the first step is a blood test, that really opens that up to communities that traditionally have been left out of screening. So I think there's a huge opportunity there, not just when we're thinking about screening for cancers that don't have screening modalities currently, but also screening for those that do, where maybe a first non-invasive step can really open the door to patients who don't have access.  So it's a long answer to say that, really, it's across the entire cancer care continuum. We see a lot of opportunity here for liquid biopsy to be a way to advance the field but also increase access for patients who have been left out of precision medicine. Dr. Rafeh Naqash: I think access is definitely the focus here. And I can give you my example. So I do early phase drug development and I do a lot of research in liquid biopsies and ctDNA monitoring. In the center of care, I treat people with lung cancer also and there have been instances, probably about a year or a year and a half back, where a patient could not come to the clinic. The clinic wasn't done and on my to-do list for that individual patient, I put in ctDNA testing just to remind me when I see the patient, to get it done. But the patient didn't make it to the clinic. Surprisingly enough, mobile phlebotomy was available. And later I came to know that this is something that can be done and provided to the patient at their home and you can still get the same results, which was very surprising in a good way. And it did help in making some treatment decisions for some patients who, sometimes in a state like Oklahoma, which is where I am based, we have a significant rural population and people drive six hours for some of our trials, especially the early phase trials. And then if you tell them, “Well, if you don't make this appointment, XYZ cannot get done,” it doesn't necessarily change things for them. So something of this sort definitely helps. Now, going to Lauren, I noticed this interesting sentence in the article, "fork in the road," where you describe, based on the current practices and policies, in the direction that we're going in, we can either increase or deepen the divide and disparities or decrease it. Could you tell us a little bit more about what currently exists on the disparity side and how do you see us narrowing that gap in the near future and implementing something that is equitable? Lauren Leiman: What's exciting about this paper is I think as we are talking about trying to condense this discussion down to something that's really digestible for everyone in the community, there are six barriers that we've identified. And I also should start by saying the working group that we have within BloodPAC that wrote this paper is intended to look at two different areas. One is that broadly, liquid biopsy still isn't available for the majority of the population domestically here in the US so that's a problem. In addition, it's clearly not available in underserved areas, and that's an even deeper divide. So we're kind of at this fork in the road because it's not broadly accessible to the majority of patients today. And so we have this moment in time where we're able to make a decision to bring everyone along with us, which is very exciting but also will take a lot of work. And these six barriers that the paper identifies, I think are very clearly articulated. They are: lack of uncertainty around test performance, the lack of familiarity with this technology, inconsistent payer coverage is an issue, mistrust of the medical establishment - especially in underserved areas, fear of discrimination in seeking this kind of technology, and the difficulty with terminology.  I think that the whole liquid biopsy community has a role to play in addressing these six areas. I think that BloodPAC, in particular, as a consortium and a collaborative process for 66 different organizations that work in the field, we have a role to play, most certainly in helping to address specifically some of these areas. We have working groups that specifically address reimbursement and policy, so that would obviously fall into payer coverage of these tests. We have working groups creating lexicons both in the molecular residual disease area, as well as our multi-cancer early detection areas. So creating terminology and lexicons that are consistent across the entire community and also digestible for patients, which is really important. And so mitigating these barriers is going to be a collaborative process across all stakeholders in the liquid biopsy field. And I think BloodPAC is uniquely positioned to address many of these  because of our diverse stakeholders and membership, which is exciting. But I do think that this is the perfect moment in time now to start addressing these challenges, and we shouldn't wait much longer, as we think through how we can bring everyone along with us and make sure we're not leaving anyone behind. Dr. Rafeh Naqash: As this entity or consortium, as you call it BloodPAC, has moved forward, this is a question for both of you, Emma and Lauren. Emma, I guess you can start. How were things five years back? What are some of the things that you have been able to achieve, and where do you potentially see the next five years? Dr. Emma Alme: I think we have made a lot of strides on the coverage side when it comes to advanced cancer testing for liquid biopsy. By no means are we there by any stretch of imagination, but we're starting to see some coverage adoption, which does make a huge difference because at the end of the day, that's so important to ensure equitable access. Especially when we're talking about a technology that has the potential to close some of the barriers in precision medicine because of the fact that you don't need access to some of the medical facilities, as you pointed out earlier, rural patients don't have access to. Because transportation is not necessarily a barrier here the way it is for some for some of these other treatment aspects. But if you don't have consistent pay or coverage, that's a place where you're really going to see drop off in terms of patients not getting equitable care and not getting standard of care as liquid biopsy enters into that realm.  The increase we've seen in private payers adopting coverage, the way we see Medicare coverage for advanced cancer liquid biopsy, is encouraging. We've seen states adopt legislation to require coverage of biomarker testing, that's passed in 15 states now, thanks to the work of the American Cancer Society and a broad coalition of stakeholders. I think that's beginning to make a difference, but we have a long road to go. We still, on the MRD side, that's just emerging. And so one space where we have some recommendations on this is continued evidence generation - continue to gather that clinical utility data that will support payer adoption increasing on the advanced cancer side, but then moving across that cancer care continuum to those other types of liquid biopsy tests. I think that's hugely important and there's a role for BloodPAC to play in that as well, especially in making sure that we bring everyone to the table to have these conversations on what is the evidence that, we need to generate, what should that look like, what are the standards to ensure that everyone feels confident in these tests. That's one area that we're really excited to see.  And I also think another space is on the diversity in clinical trials. It's so important to make sure that when we are bringing these tests to market, the data that we gather to support that is representative of all patients who can benefit. It is so important to make sure that the tests work, but also to build confidence in all of the people who are going to get these tests and feel like, “Okay. I know that this test works for patients that look like me, too.” And so that is something that at Guardant we are working really hard on. We read out our clinical trial, ECLIPSE, for our blood based test screening for colorectal cancer a little over a year ago, and we were really happy to be able to say that our trial was representative of the US population, particularly for Black Americans, where colorectal cancer incidence is increasing, 30% to 40% higher rates of mortality, in Black patients than White patients for CRC. So it's especially important to make sure that the population is representative in the clinical trial of the patients who will benefit.   And I think we are seeing companies increasingly realize their responsibility in that space and it's something that we can all really prioritize moving forward with things like making sure transportation is accessible to patients, making sure that clinical trial materials are accessible, culturally sensitive in a broad set of languages. There are a lot of different activities. You have mentioned mobile phlebotomy earlier, that can be incorporated into trials working with community centers and not just academic medical centers to ensure that the trials are taking place close to where patients live and work. This is a tractable problem and I think we've made a lot of headway in the five years. But looking to the future, there's still a lot more we can do together to ensure that work continues. Dr. Rafeh Naqash: All excellent points. And I completely agree with you. Bringing the trial to the patient is more important and likely to lead to better outcomes than the patient driving six hours to a facility to come on for trial.  So, the question for Lauren that I have from a physician or scientist standpoint, is what gets covered or does not get covered is not necessarily that I know about in my daily clinic of 15-20 patients. What is the difference between different states having different coverage policies for something like this? If it's the same payer in state A and the same payer in state B, why is the coverage policy in state B different from that in state A? And what are some of the things we can do locally and at a national level to help bridge some of these disparities and gaps? Lauren Leiman: I'm going to hand that question over to Emma. This is her bread and butter.  Dr. Emma Alme: That is such a great question, and I wish I had a more satisfactory answer for you. The reality is that when it comes to diagnostics, coverage is really a patchwork, compared to when we think about drugs whether it's FDA approved, we expect to be covered. With diagnostics, it's really up to the insurer. And I keep going back to the advanced cancer space because that's where we see the broadest coverage because it has been around the longest. But we see broad coverage from Medicare for these types of tests. But, for private payers, it's really a patchwork. We see a lot of payers only just starting to cover these tests, maybe where there's a CDX indication with an FDA-approved drug we see it, but not more broadly for tumor profiling. Especially not for the larger, more expensive comprehensive genomic profiling panels that are more expensive. I think you can extrapolate the obvious reasons why that might be. But, as this is being moving into NCCN guidelines, we see very slow adoption by some private payers.  And you touched on the legislation in different states. This coalition on American Cancer Society has been spearheading is trying to pass state-level legislation that will align coverage with a strong, robust set of evidence, and that's an FDA-approved companion diagnostic indication, medicare coverage, whether it's an NCD National Coverage Determination, a Local Coverage Determination, or National Clinical Practice Guidelines like NCCN, so really a robust set of evidence. And so this is resonating with state legislators across the country where we are seeing that take off in 15 states. But the political climate is different in different states so there are differences in terms of which state will adopt this, some of the differences are in language that they put into this. But even now that these are passing, we're seeing differential implementation, some plans are not necessarily reading this legislation and saying, “Okay, I have to cover all the tests that Medicare covers.” They are thinking that maybe they have some agency to put on other medical necessity criteria. So I think there's a lot that will play out on the individual state level to see how this nets out. But it's really kind of how different insurance companies and plans are interpreting these mandates, are interpreting guidelines, etc.  But you touched on the differences between the states and one of the things that has actually been shown in data from the precision medicine coalition is that even when you change insurance coverage for one individual plan, it doesn't necessarily translate into adoption in the direct correlation that you would expect. And part of that is because it's such a patchwork and it's so chaotic. Providers don't necessarily know for their patients which plan will cover, which one won't. They're very hesitant to subject their patients to out of pocket costs and so you get providers being reticent to order liquid biopsy just because of this coverage landscape. And so there really is that need not just to go step by step but get broader coverage for these patients across the board.  And so I think the long term vision is can we get to a change at the federal level. That's hard compared to the state level. It's a long road ahead. That's why I started this with I don't have a satisfactory answer. There is still a lot of chaos ahead even though we made some progress along the way. Dr. Rafeh Naqash: I completely agree. Lots of things to do together. But, in my daily role as a physician or a scientist, I come across situations where a patient's situation was denied for liquid biopsy, then the company went and appealed or insurance doesn't want to pay for it, and then they ask for peer-to-peer review, which is a lot of time and energy on the provider's side, the physician's side, even for as simple as a CAT scan for cancer, let alone a liquid biopsy. I started thinking at that time, is there a scenario where if I were ordering a Guardant or a foundation or any liquid biopsy for that matter, can they not provide additional support where I don't have to do a peer to peer and I can spend time and energy concentrating on the more important patient issues that are right in front of me, rather than having to wait for an insurance company to call me at a certain time of the day where I may or may not be available and then having to reschedule the call and spend another 30 minutes to them explaining. So I don't know if you guys on the other side of the aisle also think about some of these issues, but could that be a scenario that could potentially be implemented in the near future?  Dr. Emma Alme: Yes, absolutely. This is something that we at Guardant think about a lot. One of the challenges is that, as a laboratory offering liquid biopsy, you are an ancillary provider, and so I think you touched on it, a lot of this role falls to you as the physician to secure prior authorization and to be the patient's advocate. And not all plans – this is often true for Medicare Advantage – allow the laboratory to be the one to, for example, initiate prior authorization and provide the medical necessity information to make sure that that test is approved by the insurance company, and then to be the advocate for that patient in appeal process as you mentioned. And I think there is a lot of education that needs to happen among policymakers to make some tweaks to this process to ensure that the patient can have access, that the laboratory can be involved in the process where it makes sense, to smooth out this process.   And exactly right, I think you touched on a place where it is a huge burden for providers. There are places where the laboratory is best equipped to move the patient through that process and there's a lot of red tape that we can help overcome. And that's not specific to liquid biopsy. I think that's true across the diagnostics industry. But you're exactly right that it is another hurdle to access is if this is a process that has a lot of red tape. So I'm pleased to hear you think about this the same way.  Dr. Rafeh Naqash: I'm glad you guys are having those conversations, having conversations is the first important step to make a change in the near future.  If there's a patient listening out there and that patient has gotten a recent bill of $5,000 for liquid biopsy, what are some of the steps that you would like to highlight for them from a patient standpoint so that they can advocate for themselves? And should they talk to the physician in the company? Should they directly approach the company to not have that additional financial toxicity in situations where it may not be covered?   Lauren Leiman: I would 100% encourage those patients to please reach out to the company. I can only speak for Guardant but we have a patient access program. Our team calls any patient that's going to have more than $100 out of pocket because our goal at Guardant is to make sure that patients have access to the testing they need to inform their treatment and get the best possible care. I think we're all aligned across these companies across both- like we want to make sure that we are lowering the burden for cancer patients. There's already so much stress on these patients initiating treatment. They don't need to have the added stress of battling insurance. So we're here to help and no patient should be on their own in that space. So please tell your patients to reach out to the company in those instances, but I would hope that they would already have gotten outreach from the company in the first place. Dr. Rafeh Naqash: I often discuss with some of my colleagues about the financial burden of cancer care, unfortunately, that people tend to have. And I remember this scenario a couple of months back where a patient of mine, when I sat down in the clinic room, they had this big, thick folder with them. And after I finished the discussion about what was going on with the cancer, they said, "Could you help figure this out?" And they opened this folder. It had so many bills, and one of the bills was obviously a liquid biopsy bill. And that was my understanding, too, that there is a lot of resources available to these people. And eventually things worked out. The company took the cost of whatever was not being covered by the insurance. But again, you touched upon an aspect in the article about educating the physicians, the providers. I think definitely a lot of work needs to be done there so that the patients can advocate for themselves and the healthcare providers can advocate for the patients, too, like having those checks and balances and those resources present and in the institutions where these people get cared for or knowing what's the right way to channelize these issues and to whom within the companies, so that all of this gets taken care within a timely period, so that the patient doesn't come back with the same issue six months later, “I still have this bill,” that even if it's being sent to the patient or their family by mistake, it does add a lot of psychological pressure.   So I think a lot of things potentially need to be done in that space, and hopefully you guys are still doing that and continue to do that, make progress in that space to help mitigate and alleviate some of that patient level burden, which is extremely crucial in their care. Lauren Leiman: I think what's interesting about what we're looking at now is BloodPAC is thinking through these financial challenges, the coverage challenges for someone who's probably made it to an academic center to access these tests to begin with. And so to go back a little bit in the conversation, I think there still are challenges, which I'd love to hear more about from the experience of a clinician. But we have talked about, does mobile phlebotomy access everyone? Is it capable of providing access for everyone? I don't know. There's new technologies that we are looking at, like home blood collection. Most of the companies that we work with right now, they're not getting enough quantity. The quantity isn't there. But is that something that we should be pursuing? Because as you've already said, people drive six hours, and sometimes you can't make that drive. And sometimes a mobile phlebotomy lab is not able to get those six hours away. There's a limit on how far they can go. That's a huge challenge.  I'm also fascinated by the idea that if you were to eliminate coverage as an issue, so if we were to say we're offering tests for free, is there still the educational barrier, the understanding barrier that we are not putting enough emphasis on? I don't know the answer to that question. I think there is a large element to that, though. And I think that when you say education, I have asked colleagues, "Okay, guys, who are we educating? Are we educating the clinician on specific tests? Are we educating the community health worker somewhere else outside of an academic center? Are we educating the patients themselves? Do they need to really understand exactly what this kind of futuristic technology is and what it can do for them?" Those are a lot of permutations of what if, what if, what if, what is the barrier? And so to take a step back, the reality is for that big bucket of individuals that I talked about at first, yes, coverage is going to be the primary barrier for them. But if you were to remove that barrier for some individuals, I think you still have a lot of challenges left ahead of you, which is essentially what the paper is saying. But I think that that is the really big question that I still have in my mind. If we can eliminate coverage, what's left and how do we address it? Dr. Rafeh Naqash: To that point, I would like to add also- you pointed out educational barriers and there's definitely educational barriers on the provider side also, physicians, whether it's academic or community, that's a different discussion altogether. And this is not just one example, but this is an example that I'm giving because there's several other examples similar I've seen where somebody gets a liquid biopsy done in the community setting, or maybe even in an academic setting somewhere else. And somebody like me who deals with some of these results, I do a lot of precision medicine, I do a lot of genomics, but that's not everybody's interest or forte. That's not something that everybody's necessarily interested in or I try to read each and every detail in a report and understand implications, and not everybody necessarily thinks that that's the best utilization of their time. And I have identified a lot of patients that have been in the system within our state or outside our state where liquid biopsy two years back showed a certain potential germline mutation with a very high variant allele frequency and never got any germline testing. And then I see the patient and I start connecting the dots and the patient gets germline testing done - patients is positive, children are positive, children get XYZ procedures done as part of surveillance or mitigation strategies to prevent future cancers, which again, prevention is cure. At the end of the day, you catch something earlier, as we all know, higher chances for cure.  So I think that part of education, we still need to do a lot more on educating the providers, the physicians, or making it somewhat easy, like is there a way that, well, if you have a potential finding of a germline mutation, let's say on a report, instead of just mentioning the potential of germline mutations, maybe we can go to the next level and offer free germline testing and free genetic counseling and make sure that you communicate with that provider versus the responsibility being on the provider or the physician that, “Hey, did you read this carefully? Did you miss something? Did you not miss something?” This is something I have come across and we're actually doing a project right now looking at some of that and analyzing the data and the percentage is pretty significant, and hopefully, if and when the results of that project are published, you will understand how much of a difference it actually can make in the lives of patients and their families to catch something early.  Dr. Emma Alme: I think you raise a really good point and your example of germline testing along with tumor profiling is a good example of the kinds of questions that we'll encounter as liquid biopsy moves across that cancer care continuum. So I think we do have to be thinking about what kind of education will we be giving to providers for how they integrate, for example, MRD liquid biopsy testing with standard of care imaging, what does that patient management process look like? On the early cancer screening side, what happens when you get a positive test for a patient? What does that diagnostic workup look like? Especially when there isn't necessarily a standard of care screening pathway- isn't a diagnostic pathway. Whose responsibility is that? There are so many outstanding questions through how we think about provider education across this board that really will take all stakeholders together to really formulate what this looks like.  I think you raise a really good point. Right now, I think we all have more questions than answers, but I think it's an important place for us all to be working really hard on right now, to ensure that this doesn't roll out in a way where there is confusion, especially where the providers offering liquid biopsy, maybe primary care physicians who aren't necessarily, as you said, going to be well versed in the literature on liquid biopsy, thinking about these tests report the way that you are right now. There's a lot of work to be done there. Dr. Rafeh Naqash: Absolutely. It was a pleasure talking to both of you about the science, logistics, and payer aspects. A couple of quick minutes on both of you as individuals. I like to start with you, Lauren, can you tell me briefly, what's your background? How did that background connect to what you're doing today? And what else have you learned in this process? Lauren Leiman: Sure. I am Lauren Leiman. I'm the Executive Director of BlooPAC. My backgrounds are primarily in communications and business and developing collaborations that are mutually beneficial for all participants. I have worked in finance. I've worked in Africa for many years for an economist and really decided during that time that health care and health initiatives were really what interests me and ended up working in a melanoma foundation for many, many years, developing interesting collaborations between academic institutions and funding formats, and took that to the White House for the first White House Cancer Moonshot as the Head of External Partnerships, and work towards identifying collaborations between different government agencies and different companies, as well as straight corporate commitments to the Cancer Moonshot, which was “a decade of progress in half the time”, the mission statement.  And having worked in melanoma for a while and working at the Moonshot, I'd heard about this liquid biopsy technology. It's out there and I thought it was pretty cool. I have melanoma in my family, and was like, wouldn't it be really interesting if you could get your blood drawn and just tell me if I have melanoma as opposed to kind of scanning my body every six months? And my colleague Jerry Lee, at the time kind of dropped a ream of paper on my desk and said, “Read this.” So I'm neither MD nor PhD, I'm a lowly MBA, who went home and read through everything and came back and said, “You don't have a science problem. You have the collaboration problem, you need to work together, you need to share your data and share your information, which was kind of the birthplace I guess for BloodPAC - could we again, aggregate our data, bringing together these experts in the field to help accelerate the development and approval and accessibility of these technologies. That is my background. Again, an interest in things, going back to Africa and the time I spent there, I'm heavily interested in underserved populations, not just domestically but globally. My hope is that eventually BloodPAC starts really engaging in how do we increase access for all to these really exciting new tests? I do receive, BloodPAC and I as the executive director, receive calls probably once a month from different startups around the world saying, “Good luck with all your $500 test. I want a $5 test, how are we going to get there?” Which you know, I think is the absolute goal for everyone. But slowly but surely, I think we are going to work towards increasing access for all not just domestically here and not just underserved populations here in the US, but hopefully locally as well. Dr. Rafeh Naqash: Thank you, Lauren. Same question to you, Emma. Could you tell us about your background and how it led to your current work and some of the things you learned? Dr. Emma Alme: Absolutely, my background began on the science side. I did a PhD in biochemistry at UCSF University of California, San Francisco. About halfway through my PhD, which I think is a realization many have, I discovered that I loved talking about science and thinking about science and reading about science, but it would be okay if I didn't have to pick up a pipette again. At the time, I was so invigorated by all of the research going on around me but realized that, similar to what Lauren said, it wasn't the science that was the barrier in a lot of cases of this research really reaching patients and changing their care. There were so many policy barriers that were standing in the way of that that I felt like I really wanted to help tackle and so I was fortunate in the fact that there are a lot of fellowships out there for PhDs in science to move into policy roles and serve as science advisors, so I did a smattering of those all around DC. I worked at the National Academy of Science. I worked at NIH and then I went to Congress, where I was a Health Policy Fellow for Anna Eshoo and got to interact with so many different companies in the biotech space and learn about all of their amazing technology, including liquid biopsy that folks were working on where there again, were so many barriers to adoption, where there were policy solutions, and I got really excited to work on that. It was the perfect nexus of my background and biochemistry and genetics and health policy.  And so the opportunity came up to work on policy for Guardant who was really thinking about those issues. And so I jumped at the chance to spend all of my time thinking about how do we increase access for patients? How do we make sure that this innovation actually gets into their hands through changes in coverage and reimbursement? And also thinking about most of the things that we've been talking about today - diversity in clinical trials, how we brought in education for patients and providers. So it's been a really exciting space to work in. It's been super fun to get to help the Guardant work with BloodPAC and I think it's an amazing group of collaborators that brings me a little bit back to my academic roots in terms of enjoying the kind of conversations that all these folks have together as we think about standards. That's been a really exciting place for me to sit in the health policy world combining all of that experience together. Dr. Rafeh Naqash: Thank you so much. It looks like all of you within the BloodPAC and perhaps outside the BloodPAC are people driven by a common vision and mission and hopefully will succeed in all of those things that you're trying to achieve. Thank you for giving us the opportunity to talk to you guys and thank you for publishing in JCO Precision Oncology. Hopefully we'll see more of your work with regards to implementation and some of the next steps that you're taking and perhaps even the data for some of these studies that you're combining together, within JCO Precision Oncology in the near future. Dr. Emma Alme: Thank you so much for having us.  Lauren Leiman: Thank you.  Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe, so you never miss an episode.  You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Leiman COIs: Stock and Other Ownership Interests:Company: Illumina Company: Eli lillyAlme COIs:Employment: Company: Guardant Health  Stock and Other Ownership Interests: Company: Guardant Health  

CURRENT SERMON SERIES: "TIMSHOL" One of the most important words in the world is the Hebrew word “Timshol.” Steinbeck wrote about it in East of Eden. Mumford and Sons sang about it in “Timshel.” In the Bible, it appears in the story of Cain and Abel when, just before Cain murders his brother out of jealous anger, God tells him that while sin is lurking at the door, “You may master it.” Timshol means something like “You may master,” and it reminds us that we have the freedom to choose to fight through—and prevail over—our worst human impulses like anger, hatred, greed, and the need to be in control. Timshol reminds us that, by God's strength, we have the power to choose to be better humans by acting with more compassion, grace, mercy, and self-restraint. In this season of Lent, we'll explore what it means to master the impulses that make us less human by surrendering to the grace of God that, over time, perfects us in divine love.

I'm reposting this because it will be part of a film I plan to make. I became an interviewer to meet my music heroes. Jerry Lee is one I wish I'd never met. 

Johnny Sanchez and his special guest host Jaime Kay welcome to Life & Laughs a singer, author, and the former wife of twenty one years to Rock N Roll Icon Jerry Lee Lewis.... Ms. Kerrie McCarver Lewis for her very first interview since being divorced from the Killer! Kerrie, along with her manager, Mr. Norm Brewer, brings her energy filled and exciting stories of her time being married to the Killer, Jerry Lee to this fun and action packed show! We hear about the couples first meeting when Kerrie was just ten years old, how he proposed to her at twenty one, what life was like living and working with Jerry Lee, and the suspenseful story of how she literally saved Jerry Lee's life, and so much more! Check out this part one episode of two fun and exciting shows from Kerrie "Killerette" Lewis on Life & Laughs with Johnny Sanchez and his special guest Host Jaime Kay. Be sure to like, share, and subscribe to the Podcast to get a reminder sent to you each time we release a new exciting show! We would love to hear from you when you get the links to our YouTube channel and all of our social media sites at www.LifeAndLaughs.Simplecast.com. We appreciate you rating this episode and thank you so much for listening! This episode is dedicated to the Memory of Jaime Kay Lozada.Special thanks to our Emcee, Mr. Rick Vyper!Show written, edited, mixed, and produced by Johnny Sanchez!Technical Advisor - Norm BrewerRecorded at Mattie Mae Studios What listeners say about Life & Laughs with Johnny Sanchez1,094,153 channel viewsAverage customer ratingsOverall5 out of 5 stars5.0 out of 5.05 Stars Performance5 out of 5 stars5.0 out of 5.05 StarsStory5 out of 5 stars5.0 out of 5.05 Stars Life & Laughs Podcast Website: lifeandlaughs.simplecast.com Johnny's Facebook Page: facebook.com/JohnnyBSanchezLife & Laughs Facebook Page: facebook.com/LifeAndLaughsPodcastJohnny's Instagram: instagram.com/therealjohnbsanchez www.youtube.com/@LifeAndLaughsPodcast

Kerrie The Killerette Lewis is back again along with her manager Norm Brewer for part two of our incredibly entertaining interview with her on Life & Laughs with Johnny Sanchez! Kerrie was married to Rock N Roll Icon Jerry Lee Lewis for twenty one years and joins Johnny Sanchez for her very first interview since being married to the Killer! In this Life & Laughs EXCLUSIVE interview, Kerrie discusses many topics including how Jerry would escape to her parents house for days playing piano for hours for her Dad while her Mom cooked all his favorite meals and waited on him "hand and foot." We hear about his love for family and his strong faith in God, how the birth of his son Jerry Lee Lewis III changed his life, and the challenges of being married to someone that is 28 years older. We find out why they opened their ranch to the public for tours and the hilarious time Jerry Lee accidently walked in on a tour in his unmentionables. Kerrie describes what it was like dealing with the many female fans throwing themselves at her famous husband, his shocking response about it, and her funny reply, as well as whether or not she experienced any abuse in her own marriage to him. Kerrie describes her relationship in the past and present with Jerry Lee's ex wife and cousin Myra. Kerrie responds to people who thought Jerry Lee was responsible for the death of his former wife Shawn and what was going through her mind marrying him just a few months later. She also talks about the video that Jerry Lee says he got away with murder as she tells him to "shut his mouth," and the circumstances surrounding that comment. Kerrie shares her excitement about where she is at in her upcoming autobiography about all of these topics and more. Thank you so much for listening to our show! You can find out more information about the book and Kerrie by searching Killerette Lewis and Killerette Rocks on Facebook. Be sure to like, subscribe and share this episode on all of your social media. You can get links to follow us on all of our social media sites at www.LifeAndLaughs.Simplecast.com. Check out some of our video interviews and other live events at YouTube.com/Life&LaughsPodcast.This Episode is dedicated to the Memory of Jaime Kay LozadaSpecial thanks to our Emcee, Mr. Rick Vyper!Show written, edited, mixed, and produced by Johnny Sanchez!Technical Advisor - Norm BrewerRecorded at Mattie Mae Studios What listeners say about Life & Laughs with Johnny Sanchez1,094,153 channel viewsAverage customer ratingsOverall5 out of 5 stars5.0 out of 5.05 Stars Performance5 out of 5 stars5.0 out of 5.05 StarsStory5 out of 5 stars5.0 out of 5.05 Stars Life & Laughs Podcast Website: lifeandlaughs.simplecast.com Johnny's Facebook Page: facebook.com/JohnnyBSanchezLife & Laughs Facebook Page: facebook.com/LifeAndLaughsPodcastJohnny's Instagram: instagram.com/therealjohnbsanchez www.youtube.com/@LifeAndLaughsPodcast

CURRENT SERMON SERIES: "Ancient Vinyl" Before the popular Christmas hits of Mariah Carey, Bing Crosby, Wham, and Band Aid ever made the airwaves, some of the most revolutionary and inspiring songs were written by a handful of prophets and poets about a messiah who would come to his people and redeem the world.  None of their songs ever topped the charts back in their day, but 2000 years later, those ancient songs are more prophetic and hopeful than ever.  Each sings about an ever-faithful God, a world in deep turmoil, a people desperate for peace, and a savior who will come to redeem all creation. In this series, we'll play some ancient vinyl and listen once again to the five timeless tunes that once changed the world—and continue to change it even still. December 3: The Magnificat (Luke 1:46-55) December 10: The Benedictus (Luke 1:68-79) December 17: The Surge Illuminare (Isaiah 60:1-3, 11a, 14c, 18-19) December  24: The Gloria in Excelsis (Luke 2:8-14) (Christmas Eve) December 31: The Nunc Dimittis (Luke 2:22-25)

Today we discover the iconic jamming session that birthed ‘The Million Dollar Quartet' - Elvis Presley, Jerry Lee Lewis, Johnny Cash and Carl ‘Blue Suede Shoes' Perkins - who spent the day making music together at Sun Studios, Memphis on 4th December, 1956. Although the event began as an impromptu get-together, Sun's Sam Phillips was quick to call a press photographer to document the troupe, which also included Elvis's then-girlfriend, Marilyn Evans. Luckily, a savvy recording engineer also switched on the mics. In this episode, Arion, Rebecca and Olly consider why this rock n' roll quartet quickly reverted to gospel, bluegrass, blues, and country; unpick Johnny Cash's claim that he can't be heard on-mic because he was matching Presley's higher register; and marvel at Elvis's impression of Jackie Wilson… Further Reading: • ‘Million Dollar Quartet - Dec. 4 1956' (Sun Records, 2008): https://sunrecords.com/million-dollar-quartet-dec-4-1956/ • ‘Johnny Cash Elvis Presley: The story behind their epic recording session' (Daily Express, 2021): https://www.express.co.uk/entertainment/music/1424775/Johnny-Cash-Elvis-Presley-story-behind-recording-session-the-million-dollar-quartet-evg • ‘The Million Dollar Quartet' (Sun Records, 1956): https://www.youtube.com/watch?v=cOorJPVc6_M This episode first premiered in 2022, for members of

WorkTok, or CareerTok, is in full force. Combined, those hashtags on TikTok have over four billion views. There are sneak peaks into “a day in my life” from the perspective of everyone from McDonald's employees to top executives at Fortune 500s. You can hear people vent about how they struggle to nail a work-life balance and there are those who share their 9 to 5 routines and how they find time for fun things to do after work. And there are salary transparency videos and even tips from career experts on how to land a job. In fact, Gen Zers are swapping LinkedIn for TikTok, realizing they can find job opportunities in an environment that is more attuned to their career and workplace goals and hopes. Andrea Moreno, who we speak to in this episode, is one of them. She landed her job as a PR account executive thanks to a TikTok connection. Also in this episode we speak to a WorkTok creator, Jerry Lee. His account is devoted to giving career advice, including how to optimize the job search process, how to write a better resume, how to ask for a raise and even how to deal with passive aggressive co-workers. Shola West, a Gen Zer, has also dedicated her TikTok to covering career tips, leaning into building her own brand as a young professional working in media and marketing. Want to be featured in a future episode? All season we've been hearing directly from Gen Z workers about their experiences starting their careers in this new era of work. And now we want to hear from you. If you're a member of Gen Z, or a manager of one, or even a parent of one, we want to hear your thoughts on friend-torship, work-life balance, quiet quitting, and any other ways you think this new generation is changing the way we think about work. You can call and leave a voicemail at 845-580-2884 or send a voice memo to cloey@worklife.news and it might be featured in a future episode.

(Stand-alone sermon. Next series begins on Dec 3.)

CURRENT SERMON SERIES: They accused Jesus of being a radical. His message was too subversive, his influence too dangerous, his ideas just too extreme. This radical must be stopped, they said, before he changes everything. They were right. Jesus really was a radical. But he wasn't a dangerous extremist. He was simply calling people back to the roots of their faith. The word radical comes from the Latin, radix, meaning roots. To be a radical isn't to wander off to the extreme edges, but to return to the roots or the source of one's beliefs. Jesus was a radical who believed that by returning to the source—to God—we could actually change the world. In this series, we'll explore some of Jesus' most radical parables that return us to our roots—back to the source—and offer us a blueprint for how to radically transform the world around us. 

CURRENT SERMON SERIES: They accused Jesus of being a radical. His message was too subversive, his influence too dangerous, his ideas just too extreme. This radical must be stopped, they said, before he changes everything. They were right. Jesus really was a radical. But he wasn't a dangerous extremist. He was simply calling people back to the roots of their faith. The word radical comes from the Latin, radix, meaning roots. To be a radical isn't to wander off to the extreme edges, but to return to the roots or the source of one's beliefs. Jesus was a radical who believed that by returning to the source—to God—we could actually change the world. In this series, we'll explore some of Jesus' most radical parables that return us to our roots—back to the source—and offer us a blueprint for how to radically transform the world around us. 

La historia de Jerry Lee está marcada por su música del diablo y por su veloz ascenso a la cima del rock para luego despeñarse desde lo más alto quemándolo todo como quemaba su propio piano. Cuando en su primera gira por Reino Unido la prensa descubrió que la niña que lo acompañaba era su mujer y que era su prima segunda de 13 años todo acabó para Jerry.Tras ese escándalo Lewis pasó de cobrar 10.000 dólares por concierto a no más de 200. Vivió diez años en el abismo tocando cada noche saltando de ciudad en ciudad conduciendo como un loco para mantenerse a flote. Tras una década maldita salió a flote como cantante de country en los años setenta, una década marcada por sus adicciones y la muerte, la de dos mujeres y su hijo primogénito.En los años ochenta comenzó su redención y en los dos mil grabó discos muy populares con colaboradores de lujo como Bruce Springsteen o Neil Young. Esta semana dedicamos el programa a recordar la tremenda vida de Jerry Lee Lewis junto a Fernando Navarro y Lucía Taboada.

CURRENT SERMON SERIES: Jesus taught about an utterly different way of relating to the world as we know it—a way that turns the values and priorities of his followers upside-down and inside-out. In his best-known teaching, the Sermon on the Mount, he lays out a blueprint for embracing a new way of life that overturns conventional wisdom, traditional power structures, and our personal assumptions about what a “blessed” life looks like, offering a radical plan for an alternative way of being.

Dave Gaston Custom Calls' origin is a winds-like-a-snake duck hunting story that begins with western Alabama childhood, meanders through memorable friendships while chasing ducks in Mississippi and Arkansas, finds him apprenticing under one of Arkansas's most legendary call makers, and leaves him at home right where it all began. Only nowadays he spends his time carrying on on the tradition; turning duck calls as a tribute, in part, to those great people now passed. That and telling damned good stories like only Gaston can about the infamous "Jerry Lee" and other local legends. Enjoy!     __________ Gaston Custom Calls https://www.gastoncustomcalls.com __________   Podcast Sponsors: BOSS Shotshells https://bossshotshells.com/ Benelli Shotguns https://www.benelliusa.com/shotguns/waterfowl-shotguns Tetra Hearing https://tetrahearing.com/ Ducks Unlimited https://www.ducks.org Mojo Outdoors https://www.mojooutdoors.com/p Tom Beckbe https://tombeckbe.com/ Flash Back Decoys https://www.duckcreekdecoys.com/ Voormi https://voormi.com/ GetDucks.com USHuntList.com     It really is duck season somewhere for 365 days per year. Follow Ramsey Russell's worldwide duck hunting adventures as he chases real duck hunting experiences year-round: Instagram @ramseyrussellgetducks YouTube @GetDucks Facebook @GetDucks.com     Please subscribe, rate and review Duck Season Somewhere podcast. Share your favorite episodes with friends! Business inquiries and comments contact Ramsey Russell ramsey@getducks.com

Your Bandits are back, and this time you should set your butler levels to Jerry Lee, because it's time for Escape!  Oh our golly, imagination animations! How much are we paying eagles?! Clinkin' coconuts! Those poor other butler dogs?! How many rules can be broken with imagination?!  The one science butler to rule them all... may almost be... dangerously too good?!    We also get amazing incite from Trudi Monteath, one of the Art Directors that worked on this eclectically illustrated episode! She also hits us with a hard hitting question we had to truly ponder... Thanks again, Trudi!    We love you folks! For real life!  linktr.ee/watchingbluey  Twitter: @WatchingBluey Email: WatchingBluey@gmail.com  Merch: http://bit.ly/2BWBSwag  GUESS WHAT?! We have a PO Box now! If you want to send us a postcard, letter, Bluey stuff, Aussie stuff, or anything in general, send it our way!! Like a good pen pal we will respond with a hand written thank you for everything we receive with a special 2BWB postcard!!  Two Bandits Watching Bluey P.O. BOX 2372 Syracuse NY 13220  

No, I didn't make a typo. THE THIRD SATURDAY IN OCTOBER should, according to what I was told in the press email, be watched - AFTER - THE THIRD SATURDAY IN OCTOBER PART V. I talked about PART V being my cinematic comfort food; this continues my personal legacy by replicating the way I watched the NIGHTMARE ON ELM STREET movies: out of order. I caught DREAM WARRIORS first on IFC. I can only imagine how limited a '70s/'80s kid source of movie knowledge and access must've been. Hell, I had Netflix sending me DVDs. Back then, you're limited to not only the stock of what was in the video store, but also the flow of strangers renting said movie. If you needed to watch FRIDAY THE 13TH: THE FINAL CHAPTER, but all your store has is THE NEW BLOOD cause Jerry Lee is late to return the other movie, you're fucked. I write all this to say that Jay Burleson understands me, and I wildly presume he understands many of you as well. The folks who can't get enough guts and cheese in your slashers. The people who worship at the altar of Craven, Carpenter and Cunningham. Yeah, friends. And then you got Darius Willis as this movie's bad-as-a-mothafucka Dr. Loomis, Ricky Dean Logan. Just saying, he wouldn't have let Michael Myers even get to HALLOWEEN II. God bless you, Make Believe Seattle Film Festival, for introducing me to this double-feature. This should become a Halloween staple. --------------------------- Closing Song: "Workin' For MCA" - Lynyrd Skynyrd --------------------------- Review THE MOVIES on Apple Podcasts & I'll read it on the next episode! --------------------------- Follow Daniel on: Twitter - @TheMovies_Pod Instagram - @themoviespod Letterboxd - https://letterboxd.com/Daniel_Berrios/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/themoviespodcast/message

CURRENT SERMON SERIES: "Beauty for Ashes" On the outside, most of us might seem to have it all together—at least most of the time. We try to keep busy, to keep showing up, to keep up appearances, and to Keep on Truckin', as that old, familiar bumper sticker used to say. But truth be told, most of us, on the inside, are trying just to hold it all together. We stumble, fumble, and tumble through life—through triumph and tragedy, through ups and downs, through long days and dark nights—often trying desperately to protect the image we want to project in this world. Until eventually, what may appear like beauty on the outside starts to feel more like ashes on the inside. We each carry within us the shame and secrets, the betrayals and bondage, the fears and self-doubt, that come to every human life. Over time, we learn we can no longer hold these inside for the sake of holding it all together. We long for the beauty that once dwelled in us. The season of Lent is a time of cleansing and purging ourselves of the lifeless ashes we carry. By letting them out and letting them go, we make room for the grace and freedom and beauty that only God can give us. Join us for this honest and heartfelt series about God's eternal promise to bestow on each us “a crown of beauty instead of ashes.”

The night before Jerry Lee Lewis' fifth wife died, she made a phone call to her mother. She told her that she was thinking of leaving the rock ‘n' roll pioneer, but that he wouldn't let her. She also made a second call—this one to the sister of her high school sweetheart, making plans for the sister to come take her away from Jerry Lee later that month. Then … in mid-sentence the phone went dead. The next day, Mrs. Jerry Lee Lewis was found dead. Placed nearly on top of a perfectly made bed in the newlywed couple's guest room. Despite the bruises on her body, the blood under her fingernails, the scratches on her husband's hands, and the mountain of other physical and anecdotal evidence, the death was ruled an accident. Did Jerry Lee Lewis kill his wife and get away with murder? To see the full list of contributors, see the show notes at www.disgracelandpod.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Have you ever sat through a day of professional development and thought to yourself, how in the world does this connect to me and my students? You may not be alone! Listen in, as Jerry Lee, Principal at Woodlawn Elementary School in Florida, shares with Molly how their school takes a Win-Win approach to professional development.

New Years' Day Sermon

Christmas Morning Sermon

Content warning: in this episode we discuss some upsetting topics related to Jerry Lee Lewis's personal controversies. Yes, following his recent passing and recent induction into the Country Music Hall of Fame, this week we talk Rock 'N Roll's original wild man. Joined by comedian Charlie Vergos (@cvergos, Barbecue Rich), the boys dig into JLL's complicated legacy, his prolific country music career, and his infamously unhinged behavior and lack of self control.Get bonus episodes, blog posts, and more by supporting us on Patreon HERE! (The more patrons we have, the more bonus episodes we release! Thanks for your support!)You heard some clips in the episode, but if you're curious, here are some other key tracks The Killer:Me and Bobby McGeeYou Win AgainGreat Balls of FireWhole Lot of Shakin' Going OnSave The Last Dance For MeWhat's Made Milwaukee Famous (Has Made A Loser Out of Me)I Can Still Hear The Music In The RestroomWine Me UpMoney (That's What I Want)Follow the link below to keep up with which songs are being added to our Ultimate Country Playlist on Spotify, now including Jerry Lee's cover of "Jambalaya (On The Bayou)"!https://tinyurl.com/takethispodplaylist And on TIDAL!https://t.co/MHEvOz2DOACheck out our Patreon!Check out our new merch store!For everything else click HERE!

We play a trio of tunes honoring the late, great Jerry Lee Lewis who passed away on October 28th at 87 years old.  There's a live track from 1964 from him, Jimmy Page teaming up with Jerry Lee on a Led Zeppelin cover and a Killer cover from The 5678's!  Beth Riley has a deep track from The Beach Boys on her Surf's Up: Beth's Beach Boys Break.  We also play the final track from their That's Why God Made The Radio release as we finish up our 10th anniversary celebration of that release and we'll drop a coin in the Jammin' James Jukebox for our selection of the week.  Plus, there's great tunes in the mix from Frankie and The Pool Boys, Ichi-Bons, The Malibooz, The Green Reflectors, The Eye Five, Wiped Out, Master Wave, Lucky 757, High Noon Kahuna, Messer Chups, Jim & The Sea Dragons, The Courettes and Sys Malakian!   Intro music bed: "Catch A Wave"- The Beach Boys   The Green Reflectors- "Cruisin' For A Bruisin'" Wiped Out- "The Hearse" Sys Malakian- "Dolphin Ride" The Courettes- "Bye Bye Mon Amour" Messer Chups- "Night Stripper" Jim & The Seadragons- "The Murder Hornet Twist" High Noon Kahuna- "Sharktooth" Lucky 757- "Let's Get Ready"   Surf's Up: Beth's Beach Boys Break: The Beach Boys- "Slip On Through" Follow "Surf's Up: Beth's Beach Boys Break" HERE   The Malibooz- "Sweet Surf Music"   Jerry Lee Lewis tribute: Jerry Lee Lewis- "Good Golly, Miss Molly" (live) Jerry Lee Lewis with Jimmy Page- "Rock And Roll" The 5678's- "Great Balls Of Fire"   10th Anniversary Celebration of The Beach Boys- That's Why God Made The Radio The Beach Boys- "Summer's Gone"   Frankie and The Pool Boys- "The Stargazers"   Jammin' James Jukebox selection of the week: The Cornells- "Beachbound"   The Eye Five- "Coast Ghost" Ichi-Bons- "Snake Eyes" (live) Monster Wave- "Lighthouse Lagoon"   Outro music bed:  Jerry Lee Lewis- "High School Confidential"

We mark the life of the rock 'n' roll pioneer, who died Oct. 28, by listening to archival interviews with his sister, pianist/singer Linda Gail Lewis, and with Myra Lewis Williams, who married Jerry Lee when she was 13. And Ken Tucker reflects on Lewis' 1968 country album.

The Rock and Roll revolution started in America with Jerry Lee Lewis and Elvis, with roots in Pentecostal churches. Here is another story of Americana, which ends with the unleashing of a sexual revolution, undoubted demonic influence, and what may or may not be repentance at the end. We cover Jerry Lee Lewis, and the recent biographies of Johnny Cash and his spiritual journey and questions posed at the end of his life. Here's the takeaway: America has deep Christian roots. America is in apostasy. There is always room to repent all the way to the end for the thief on the cross. This program includes: 1. The World View in 5 Minutes with Adam McManus (Oprah's hypocritical endorsement of John Fetterman, Cast a Biblically-informed vote, Myanmar Bible School shelled by Burmese Army) 2. Generations with Kevin Swanson

The Rock and Roll revolution started in America with Jerry Lee Lewis and Elvis, with roots in Pentecostal churches. Here is another story of Americana, which ends with the unleashing of a sexual revolution, undoubted demonic influence, and what may or may not be repentance at the end. We cover Jerry Lee Lewis, and the recent biographies of Johnny Cash and his spiritual journey and questions posed at the end of his life. Here's the takeaway- America has deep Christian roots. America is in apostasy. There is always room to repent all the way to the end for the thief on the cross.--This program includes---1. The World View in 5 Minutes with Adam McManus -Oprah's hypocritical endorsement of John Fetterman, Cast a Biblically-informed vote, Myanmar Bible School shelled by Burmese Army---2. Generations with Kevin Swanson

So ok… I was assigned the death of Jerry Lee “The Killer” Lewis and his questionable past. So I did what I could. Never meet your heroes, I guess, cuz they're humans. VOTE IN THE MIDTERMS! Homework: https://www.latimes.com/entertainment-arts/music/story/2022-10-28/jerry-lee-lewis-myra-gale-brown-third-wife-bookRecorded LIVE at the Green Mill Cocktail Lounge in Chicago 10/29/22Brought to you by Jeppson's Mälort: Aiding in Social Distancing since the 1930's The Patreon is LIVE and we need money. Featuring “Promises” by the Barrerracudas and a snippy of “SOLO ACOUSTIC GUITAR” by Jason Shaw http://freemusicarchive.org/music/Jas... Creative Commons — Attribution-ShareAlike 3.0 Unported— CC BY-SA 3.0PLEASE RATE AND REVIEW, VOTE VOTE VOTE! And as aways: BLACK LIVES MATTER, MASK, VAX and BOOST, DOWN WITH THE SCOTUS!

As promised, here is the full interview Steve Jones did with the legendary rock n roller Jerry Lee Lewis, who passed away last week at the age of 87. The episode is from an appearance Lewis made September 6, 2006, at Indie 103.1, in support of his album Last Man Standing. Record promotion executive Michael Plen had arranged to deliver a piano to the studio, and Lewis was set to perform live on the show. Things went downhill from the moment he entered the radio studio. As soon as he saw the piano, Lewis snarled, “What's that thing doing here? I ain't playing no goddamn piano!” Despite the tension, the rapport between the two musical rebels was going great until Jonesy brought up the problems Lewis had on his trip to London in 1958.  The Killer's demeanor shifted dramatically because Jonesy was referring to the notorious UK tour that began with a career-crushing press conference at London's Heathrow airport.  Myra Gale Brown, the 13-year-old girl accompanying Lewis, told a reporter she was Lewis's new wife. It was later revealed that Myra was also Lewis' cousin. After that, the tension in the radio studio was as thick as pea soup. In a rare moment, Jonesy was lost for words. Not to waste a good piano, you'll hear Jonesy doing some great Jerry Lee-style boogie on the keys at the beginning and end of the show. Enjoy this memorable episode, and if you haven't yet, subscribe to Jonesy's Jukebox. It's free!

Rockshow episode 169 Jerry Lee Lewis The show was scheduled for December but because of the recent death of Jerry Lee Lewis we moved it up the schedule. So watch and celebrate the the life of Jerry Lee Lewis and thank you for subscribing. Jerry Lee Lewis (September 29, 1935 – October 28, 2022) was an American singer, songwriter and pianist. Nicknamed "the Killer", he was described as "rock and roll's first great wild man and one of the most influential pianists of the 20th century". A pioneer of rock and roll and rockabilly music, Lewis made his first recordings in 1952 at Cosimo Matassa's J&M Studio in New Orleans, Louisiana, and early recordings in 1956 at Sun Records in Memphis, Tennessee. "Crazy Arms" sold 300,000 copies in the South, and his 1957 hit "Whole Lotta Shakin' Goin' On" shot Lewis to fame worldwide. He followed this with the major hits "Great Balls of Fire", "Breathless", and "High School Confidential". His rock and roll career faltered in the wake of his marriage to Myra Gale Brown, his 13-year-old cousin once removed. Lewis had a dozen gold records in rock and country. He won four Grammy awards, including a Grammy Lifetime Achievement Award and two Grammy Hall of Fame Awards.Lewis was inducted into the Rock and Roll Hall of Fame in 1986 and his pioneering contribution to the genre was recognized by the Rockabilly Hall of Fame. He was also a member of the inaugural class inducted into the Memphis Music Hall of Fame. He was inducted into the Country Music Hall of Fame in 2022. In 1989, his life was chronicled in the movie Great Balls of Fire, starring Dennis Quaid. In 2003, Rolling Stone listed his box set All Killer, No Filler: The Anthology at number 242 on their list of "500 Greatest Albums of All Time". In 2004, they ranked him No. 24 on their list of the 100 Greatest Artists of All Time. Lewis was the last surviving member of Sun Records' Million Dollar Quartet and the album Class of '55, which also included Johnny Cash, Carl Perkins, Roy Orbison, and Elvis Presley. Music critic Robert Christgau said of Lewis: "His drive, his timing, his offhand vocal power, his unmistakable boogie-plus piano, and his absolute confidence in the face of the void make Jerry Lee the quintessential rock and roller." https://jerryleelewis.com/ https://m.facebook.com/JerryLeeLewis/ https://www.rollingstone.com/music/music-news/jerry-lee-lewis-dead-obituary-1234616945/amp/ https://open.spotify.com/artist/2zyz0VJqrDXeFDIyrfVXSo https://www.instagram.com/jerryleelewisthekiller/?hl=en https://m.youtube.com/watch?v=4bB5xL577r4&autoplay=1 https://twitter.com/jerryleelewis?lang=en @Jerryleelewis @Greatballsoffire @Thekiller @breathless @sunrecord @pianoplayer @rockabilly #Jerryleelewis #greatballsoffire #rockabilly #rocknroll #piano #sunrecord Please follow us on Youtube,Facebook,Instagram,Twitter,Patreon and at www.gettinglumpedup.com https://linktr.ee/RobRossi Get your T-shirt at https://www.prowrestlingtees.com/gettinglumpedup And https://www.bonfire.com/store/getting-lumped-up/ https://app.hashtag.expert/?fpr=roberto-rossi80 https://dc2bfnt-peyeewd4slt50d2x1b.hop.clickbank.net Subscribe to the channel and hit the like button This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/rob-rossi/support https://itunes.apple.com/us/podcast/getting-lumped-up-with-rob-rossi/id1448899708 https://open.spotify.com/show/00ZWLZaYqQlJji1QSoEz7a https://www.patreon.com/Gettinglumpedup --- Support this podcast: https://anchor.fm/rob-rossi/support

More recalls… Move to Bali?... Powerball / no winner… New App for shakes… Socials and Emails… Ye... Rihanna release comin up… Who Died Today: Ash Carter 68… Jerry Lee falsely reported dead… Smell of human in buried car… Off the cliff she went… Darrell Brooks Jr. Guilty all counts… New Covid Wave?... Ports not backed up… Rail strike comin?... Joke of the day not needed…    Learn more about your ad choices. Visit megaphone.fm/adchoices

Jerry Lee is the co-founder and COO of Wonsulting, a company that teaches people the skills they need to go after their dream job. Jerry has a range of clients, from college students trying to land internships to seasoned professionals trying to make the next big step in their career. The post What It's Like to Be a COO at 25 With Jerry Lee, Wonsulting [re-release] appeared first on Time4Coffee.